Ivabradine Shows Promise as Tx for Hyperadrenergic POTS

Further study needed in other POTS subtypes In patients with hyperadrenergic postural orthostatic tachycardia syndrome (POTS), one month of treatment with ivabradine brought about significant improvements in several parameters, including heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels, according to results from a recent study published in the Journal of the American

Postural Tachycardia Syndrome and COVID-19: Focus on Ivabradine

Acute hyperhidrosis and postural tachycardia in a COVID-19 patient

PDF) Cognitive Dysfunction in Postural Tachycardia Syndrome.

Dysautonomia International - Great new research from Vanderbilt's

Postural Tachycardia Syndrome: Beyond Orthostatic Intolerance

PDF) Ivabradine in Postural Orthostatic Tachycardia Syndrome: A

Randomized Trial of Ivabradine in Patients With Hyperadrenergic

Ivabradine in children with postural orthostatic tachycardia

Frontiers Chronic Treatment with Ivabradine Does Not Affect